23andMe sold the rights to a drug it developed from its genetic database


The genetics testing company 23andMe licensed the rights to a drug it developed in-house to a Spanish pharmaceutical company, Bloomberg reported. This is the first time that the company has directly sold a product it created using the genetic information collected from users.

23andMe has already shared genetic data with pharmaceutical companies. GlaxoSmithKline has the exclusive rights to use its data for drug development, and purchased a $300 million stake in the company in 2018. But those drug companies use the company’s data to create their own drugs. In this case, 23andMe identified a drug candidate and conducted animal studies on that drug internally before selling it. The Spanish company, Almirall, will take the product through human trials.

“We’ve now gone from database to discovery to developing a drug,” Emily Drabant Conley, 23andMe’s vice president of business development, told Bloomberg.

The company’s repository of genetic and health data is a gold mine for drug development because researchers can look for relationships between particular genes and health outcomes and target them with therapeutics. The company has genetic data on around 10 million people, and it says around 80 percent agreed to let their anonymized data be used for research, including drug research. The terms of service say that customers who agree to let their data be used will not see any financial benefit, even if that data helps develop a blockbuster drug.

The drug the company sold to Almirall is a molecule that blocks signals from small proteins that are involved in autoimmune diseases. 23andMe targeted the compound to treat psoriasis, an autoimmune disease that causes red and scaly skin patches.

The post 23andMe sold the rights to a drug it developed from its genetic database appeared first on NewsCetera.

Visit the USSA News store!
Click this link for the original source of this article.
Author: Addison Walsh

This content is courtesy of, and owned and copyrighted by, https://newscetera.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact the USSANews.com administrator by using the contact form located in the top-left menu. Your request will be immediately honored. Please visit https://newscetera.com for more terrific, conservative content. The owner of this website may be paid to recommend American Bullion. The content of this website, including the positive review of American Bullion, the negative review of its competitors, and any other information may not be independent or neutral.

https://beyondlimitsvacation.com USSANews.com